CLSD Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 23:00):

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space...

Stats
Šios dienos apimtis	182 482
Vidutinė apimtis	379 738
Rinkos kapitalizacija	99.39M
EPS	$0 ( 2024-05-09 )
Kita pelno data	( $-0.140 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.42
ATR14	$0.00900 (0.68%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Yerxa Benjamin R	Buy	7 813	Common Stock
2024-04-18	Gibney Anthony S	Buy	93 290	Common Stock
2024-04-17	Gibney Anthony S	Buy	6 710	Common Stock
2024-04-15	Gibney Anthony S	Buy	45 000	Stock Option (right to buy)
2024-04-15	Gibney Anthony S	Buy	0

INSIDER POWER
67.80
Last 97 transactions
Buy: 5 503 181 \| Sell: 2 142 358

Tūris Koreliacija

Ilgas: -0.15 (neutral)

Trumpas: 0.00 (neutral)

Signal:(50.988) Neutral

Clearside Biomedical Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Clearside Biomedical Inc Koreliacija - Valiuta/Žaliavos

0.30
( neutral )

0.24
( neutral )

0.00
( neutral )

0.27
( neutral )

0.00
( neutral )

-0.36
( neutral )

Clearside Biomedical Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$8.23M
Bruto pelnas:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2023
Pajamos:	$8.23M
Bruto pelnas:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2022
Pajamos:	$1.33M
Bruto pelnas:	$1.12M (84.63 %)
EPS:	$-0.570

FY	2021
Pajamos:	$29.58M
Bruto pelnas:	$29.58M (100.00 %)
EPS:	$0.00632

Financial Reports:

No articles found.

Clearside Biomedical Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.